Introduction to Midd Training Module 2 Part Two
Let's dive into the details surrounding Midd Training Module 2 Part Two. Stacy Tannenbaum, the lead of the Pharmacometrics Group in the US for Astellas Pharma Global Development, discusses ...
Midd Training Module 2 Part Two Comprehensive Overview
Stacy Tannenbaum, lead of the Pharmacometrics Group in the US for Astellas Pharma Global Development, reviews the various ... This lecture by Dr. Rajesh Krishna is a case study showing how anti-viral kinetic modeling can be used to support drug ... This lecture by Jeffrey Barrett from the Critical Path Institute describes the
Dr. Qi Liu, the Assoc. Director for Innovation & Partnership in the Office of Clinical Pharmacology, Office of Translational Sciences ...
Summary & Highlights for Midd Training Module 2 Part Two
- Jeffrey Barrett from the Critical Path Institute provides the overview of this
- This lecture by Drs. Adekemi, Taylor, Rajesh Krishna and S.Y. Amy Cheung, Senior Directors of Integrated Drug Development at ...
- This lecture is
- Dr. Mark R. Gasronguay, Founder and CEO of the Metrum Research Group, discusses how to use simulation from a mathematical ...
- Clinical Pharmacologist Dr. Colin Pillai discusses if there are differences between an industry versus a regulatory setting, or if ...
That wraps up our extensive overview of Midd Training Module 2 Part Two.